Human immunodeficiency virus type 1 protease inhibitor attenuates Candida albicans virulence properties in vitro

被引：49

作者：

Gruber, A

Speth, C

Lukasser-Vogl, E

Zangerle, R

Borg-von Zepelin, M

Dierich, MP

Würzner, R

机构：

[1] Univ Innsbruck, Ludwig Boltzman Inst AIDS Forsch, A-6020 Innsbruck, Austria

[2] Univ Innsbruck, Inst Dermatol & Venereol, A-6020 Innsbruck, Austria

[3] Univ Gottingen, Inst Hyg, D-3400 Gottingen, Germany

来源：

IMMUNOPHARMACOLOGY | 1999年 / 41卷 / 03期

基金：

奥地利科学基金会;

关键词：

Candida albicans; Indinavir; HIV-1;

D O I：

10.1016/S0162-3109(99)00035-1

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The putative virulence factor secreted aspartyl proteinase (SAP) of Candida albicans and the human immunodeficiency virus type 1 (HIV-1) protease both belong to the aspartyl proteinase family. The present study demonstrates that the HIV-1 protease inhibitor Indinavir is a weak but specific inhibitor of SAP. In addition, Indinavir reduces the amount of cell bound as well as released SAP antigen from C. albicans. Furthermore, viability and growth of C. albicans are markedly reduced by Indinavir, These findings indicate that HIV-1 protease inhibitors may possess antifungal activity and we speculate that in vivo SAP inhibition may add to the resolution of mucosal candidiasis in HIV-1 infected subjects. (C) 1999 Elsevier Science B.V. All rights reserved.

引用

页码：227 / 234

页数：8

共 50 条

[41] Human immunodeficiency virus type-1 (HIV-1) replication is unaffected by human secretory leukocyte protease inhibitor
Turpin, JA
Schaeffer, CA
Bu, M
Graham, L
Buckheit, RW
Clanton, D
Rice, WG
ANTIVIRAL RESEARCH, 1996, 29 (2-3) : 269 - 277
[42] Increased expression of virulence attributes in oral Candida albicans isolates from human immunodeficiency virus-positive individuals
Mane, Arati
Gaikwad, Shraddha
Bembalkar, Shilpa
Risbud, Arun
JOURNAL OF MEDICAL MICROBIOLOGY, 2012, 61 (02) : 285 - 290
[43] Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin
Parikh, S
Liu, J
Sijwali, P
Gut, J
Goldberg, DE
Rosenthal, PJ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) : 2207 - 2209
[44] Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir
Resch, W
Parkin, N
Watkins, T
Harris, J
Swanstrom, R
JOURNAL OF VIROLOGY, 2005, 79 (16) : 10638 - 10649
[45] Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen
Gianotti, N
Seminari, E
Lazzarin, A
Boeri, E
Clementi, M
Danise, A
Salpietro, S
Fusetti, G
Castagna, A
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (06) : 545 - 554
[46] Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir
Baxter, John D.
Schapiro, Jonathan M.
Boucher, Charles A. B.
Kohlbrenner, Veronika M.
Hall, David B.
Scherer, Joseph R.
Mayers, Douglas L.
JOURNAL OF VIROLOGY, 2006, 80 (21) : 10794 - 10801
[47] Fixed drug eruptions to human immunodeficiency virus-1 protease inhibitor
Smith, KJ
Yeager, J
Skelton, H
CUTIS, 2000, 66 (01): : 29 - 32
[48] Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors
Parikh, S
Gut, J
Istvan, E
Goldberg, DE
Havlir, DV
Rosenthal, PJ
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (07) : 2983 - 2985
[49] Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease
Fehér, A
Boross, P
Sperka, T
Miklóssy, G
Kádas, J
Bagossi, P
Oroszlan, S
Weber, IT
Tözsér, J
JOURNAL OF GENERAL VIROLOGY, 2006, 87 : 1321 - 1330
[50] Fitness landscape of human immunodeficiency virus type 1 protease quasispecies
Fernandez, Guerau
Clotet, Bonaventura
Martinez, Miguel Angel
JOURNAL OF VIROLOGY, 2007, 81 (05) : 2485 - 2496

← 1 2 3 4 5 →